PAB · ASX

Patrys Limited (ASX:PAB)

AU$0.004

 0.0 (0.0%)
ASX:Live
25/12/2024 12:00:00 AM
HALO Ords GROWTH AUS Big Candle All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PAB Overview

PAB Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About PAB

Website

Patrys Limited

Telephone

61.3.9670.3273

Address

Level 4 100 Albert Road South Melbourne, Victoria (VIC) 3205

Description

Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. Its pipeline includes PAT-DX1 antibody fragment, PAT-DX3 full sized antibody, and PAT-DX1-NP conjugated to nanoparticles. The company was founded by Daniel Devine on December 8, 2006 and is headquartered in South Melbourne, Australia.

PAB Price Chart

Key Stats

Market Cap

AU$8.23M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.01

Trade Value (12mth)

AU$1,863.00

1 week

0%

1 month

0%

YTD

-50%

1 year

-50%

All time high

0.62

Key Fundamentals

EPS 3 yr Growth

-32.00%

EBITDA Margin

N/A

Operating Cashflow

-$2m

Free Cash Flow Return

-35.20%

ROIC

-68.70%

Interest Coverage

N/A

Quick Ratio

5.50

Other Data

Shares on Issue (Fully Dilluted)

2056m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PAB Announcements

Latest Announcements

Date Announcements

24 December 24

Notification of cessation of securities - PAB

×

Notification of cessation of securities - PAB

24 December 24

Change of Director's Interest Notices x3

×

Change of Director's Interest Notices x3

16 December 24

Patrys Receives R&D Tax Incentive Refund

×

Patrys Receives R&D Tax Incentive Refund

22 November 24

Chair's Address and CEO Presentation to 2024 AGM

×

Chair's Address and CEO Presentation to 2024 AGM

22 November 24

Results of Annual General Meeting

×

Results of Annual General Meeting

30 October 24

Appendix 4C - Quarterly - 30 September 2024

×

Appendix 4C - Quarterly - 30 September 2024

21 October 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

14 October 24

Notification of cessation of securities - PAB

×

Notification of cessation of securities - PAB

02 October 24

PAT-DX1 clinical development update

×

PAT-DX1 clinical development update

20 September 24

PAT-DX1 GMP specification testing update

×

PAT-DX1 GMP specification testing update

29 August 24

PAT-DX1 GMP specification testing update

×

PAT-DX1 GMP specification testing update

23 August 24

Appendix 4E and 2024 Annual Report

×

Appendix 4E and 2024 Annual Report

23 August 24

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

29 July 24

Further update on PAT-DX1 GMP manufacturing run

×

Further update on PAT-DX1 GMP manufacturing run

23 July 24

Appendix 4C - Quarterly - 30 June 2024

×

Appendix 4C - Quarterly - 30 June 2024

01 July 24

Update on GMP manufacturing run of PAT-DX1

×

Update on GMP manufacturing run of PAT-DX1

30 April 24

Appendix 4C - Quarterly - 31 March 2024

×

Appendix 4C - Quarterly - 31 March 2024

09 April 24

Positive preclinical data for deoxymabs in vasculitis

×

Positive preclinical data for deoxymabs in vasculitis

22 March 24

Notification of cessation of securities - PAB

×

Notification of cessation of securities - PAB

22 March 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

04 March 24

Presentation to highlight broader potential of Deoxymabs

×

Presentation to highlight broader potential of Deoxymabs

23 February 24

Appendix 4D - Half Year Accounts - 31 December 2023

×

Appendix 4D - Half Year Accounts - 31 December 2023

23 January 24

Appendix 4C - Quarterly - 31 December 2023

×

Appendix 4C - Quarterly - 31 December 2023

22 December 23

Change of Director's Interest Notice

×

Change of Director's Interest Notice

13 December 23

GMP Production of PAT-DX1 Next Quarter

×

GMP Production of PAT-DX1 Next Quarter

PAB Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -40.0 2.9 50.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -51.6 -6.3 49.2 Lock Lock Lock
     Yield % Lock Lock Lock Lock -22.1 -28.1 -12.6 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -0.3 -50.4 -51.6 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 1,961 2,055 2,056 Lock Lock Lock
Basic m Lock Lock Lock Lock 1,961 2,055 2,056 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 -100.0 N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 11 10 5 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A -0.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.0 N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -10 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -95.0 13.4 50.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -41,189.7 N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -11 -10 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -94.2 13.3 50.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -41,362.6 N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -12 -10 -5 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -5 -3 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -7 -7 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -66.9 -4.1 49.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -24,655.9 N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -9 -6 -2 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 2 1 1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 8 0 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -9 -6 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -123.7 33.4 68.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -315.7 N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 8 4 2 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 14 8 4 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -8 -4 -2 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 13 7 3 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 13 7 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 11.5 -49.1 -49.2 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -48.5 -93.8 -85.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -50.5 -103.3 -102.0 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -89.3 -97.3 -95.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -53.2 -69.7 -68.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -68.2 -57.0 -35.2 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.7 0.4 0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -58.2 -59.2 -64.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 24.9 10.4 5.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 24.9 10.4 5.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 57.8 56.7 58.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -1,598.9 -841.3 -263.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 587.9 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -42,064.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -82.8 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -48.5 -93.8 -85.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.1 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -50.5 -103.3 -102.0 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -50.5 -103.3 -102.0 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 31,115.6 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 31,115.6 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 0.0 1,755.7 2,054.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 31,115.6 -1,755.7 -2,054.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PAB Shortsell

Frequently Asked Questions

The current share price of Patrys Limited (PAB:ASX) is AU$0.004.
The 52-week high share price for Patrys Limited (PAB:ASX) is AU$0.01.
The 52-week low share price for Patrys Limited (PAB:ASX)? is AU$0.00.
Patrys Limited (PAB:ASX) does not pay a dividend.
Patrys Limited (PAB:ASX) does not pay a dividend.
Patrys Limited (PAB:ASX) has a franking level of 0.0%.
Patrys Limited (PAB:ASX) is classified in the Healthcare.
The current P/E ratio for Patrys Limited (PAB:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.